Compare FDUS & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDUS | IRWD |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.6M | 663.6M |
| IPO Year | 2011 | 2009 |
| Metric | FDUS | IRWD |
|---|---|---|
| Price | $19.07 | $4.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $21.00 | $7.67 |
| AVG Volume (30 Days) | 317.8K | ★ 2.2M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.49% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | ★ 0.65 | 0.24 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $9.39 | $57.95 |
| Revenue Next Year | $8.79 | $4.39 |
| P/E Ratio | $29.14 | ★ $17.92 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $16.87 | $0.67 |
| 52 Week High | $22.09 | $5.78 |
| Indicator | FDUS | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 57.68 | 64.54 |
| Support Level | $18.65 | $3.80 |
| Resistance Level | $19.36 | $4.50 |
| Average True Range (ATR) | 0.37 | 0.23 |
| MACD | 0.07 | 0.09 |
| Stochastic Oscillator | 92.97 | 89.61 |
Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investment is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.